# A GBT021601 ADME Microtracer Study in Healthy Volunteers

> **NCT05718687** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT021601

## Key facts

- **NCT ID:** NCT05718687
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-22
- **Primary completion:** 2023-08-10
- **Final completion:** 2023-08-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718687, "A GBT021601 ADME Microtracer Study in Healthy Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05718687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*